Arthneeti
Latest: Alembic Pharmaceuticals Ltd Q1 FY27 results →All Q3 FY26 results →
AP

Alembic Pharmaceuticals Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Alembic Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Price₹822
Market cap₹16.1K Cr
P/E21.6
Updated23 Aug 2026
Read3 min read

The short version

U.S. U.S.

From Alembic Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • U.S. business expected to grow at a mid-teens constant currency rate (~10-15%) through FY '27 and '28, driven by volume growth and new launches despite pricing pressures.
  • ROW (Rest of World) markets saw 36% growth, indicating strong geographic expansion opportunities.
  • India branded business aiming to catch up with or exceed market growth by next fiscal year (FY '27), focusing on operational improvements and launches.
  • Upcoming launches in U.S., including the first branded product Pivya, expected to scale prescription share over 12–18 months, contributing to incremental revenue.
  • Injectable, peptides, drug-device combinations, and complex products targeted for growth over next 2-3 years.

2 more points from Alembic Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No plans for large expansions currently, as per Shaunak Amin (Page 12).
  • Focus on better capacity utilization of existing facilities, expected to drive margin expansion in upcoming quarters (Page 14).
  • Strategic contracts and in-house products in injectable and oncology are expected to scale utilization of new facilities over next 12 to 18 months (Page 6).

2 more points from Alembic Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights include: - The company has executed several out-licensing and manufacturing agreements supporting injectable and oncology capabilities, expected to help scale utilization over the next 12 to 18 months. - There is a momentum of new product launches, including 2 approved products launched in Q3 and plans to launch another 4-5 products in Q4. - The first branded product launch in the U.S., Pivya, is on track for Q4 FY '26, expected to scale prescription share over 12 to 18 months.

2 more points from Alembic Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.8K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Alembic Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules Ltd (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn Ltd (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharmaceuticals Ltd (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alembic Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alembic Pharmaceuticals Ltd Q3 FY26 results?

U.S. U.S.

What is Alembic Pharmaceuticals Ltd share price analysis?

Alembic Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 21.6 with a market cap of ₹16,083 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alembic Pharmaceuticals Ltd planning capital expenditure?

No plans for large expansions currently, as per Shaunak Amin (Page 12).

Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.